Node1	Edge_Type	Node2	Weight	Score	Paper_List	Original_Text
palmitoylethanolamide	chemical	risperidone	1	3.745	29807317	PMID:29807317; Original text:Meanwhile, there was a trend toward significance for superior effect of risperidone plus Palmitoylethanolamide over risperidone plus placebo on inappropriate speech at trial endpoint (d = 0.51, p = 0.051).
glutamine	chemical	vitamin b6	1	3.998	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
luteolin	chemical	rapamycin	1	5.793	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
creatine	chemical	gaba	1	5.902	23370056	PMID:23370056; Original text:The ratio of GABA to Creatine was significantly lower in the autism spectrum disorders group than the control subjects.
valproate	chemical	vpa	1	2.195	16190799	PMID:16190799; Original text:In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with pervasive developmental disorders and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients.
ammonia	chemical	vpa	1	2.195	16190799	PMID:16190799; Original text:Two subjects receiving VPA developed increased serum ammonia levels, one with an associated parent report of slurred speech and mild cognitive slowing.
homovanillic acid	chemical	hva	1	1.0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
b6-mg	chemical	homovanillic acid	1	1.0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
biochemical	chemical	homovanillic acid	1	1.0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
b6-mg	chemical	hva	1	1.0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
biochemical	chemical	hva	1	1.0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
b6-mg	chemical	biochemical	1	1.0	7124567	PMID:7124567; Original text:Biochemical data analysis revealed that a significant decrease in urinary homovanillic acid (HVA) levels was observed during B6-Mg administration.
desipramine	chemical	fluvoxamine	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
desipramine	chemical	serotonin	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	desipramine	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
desipramine	chemical	paroxetine	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
clomipramine	chemical	desipramine	2	7.189	11085201|8498878	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.|PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
fluvoxamine	chemical	serotonin	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	fluvoxamine	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
fluvoxamine	chemical	paroxetine	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
clomipramine	chemical	fluvoxamine	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	serotonin	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
paroxetine	chemical	serotonin	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
clomipramine	chemical	serotonin	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	paroxetine	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
citalopram	chemical	clomipramine	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
clomipramine	chemical	paroxetine	1	6.189	11085201	PMID:11085201; Original text:In patients with obsessive-compulsive disorder, fluvoxamine had similar efficacy to that of clomipramine and, in smaller trials, the a potent and selective serotonin reuptake inhibitors paroxetine and citalopram and was significantly more effective than desipramine.
fluvoxamine	chemical	imipramine	1	6.189	11085201	PMID:11085201; Original text:Fluvoxamine < or = 300 mg/day for 6 to 8 weeks was as effective as imipramine in patients with panic disorder, and significantly more effective than placebo.
glutathione	chemical	s-adenosylmethionine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	vitamin b12	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	vitamin d	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	glutathione	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	glutathione	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	methionine	2	6.28	33414386|24676906	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
glutathione	chemical	vitamin e	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	vitamin b9	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical	s-adenosylhomocysteine	2	6.28	33414386|24676906	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
s-adenosylmethionine	chemical	vitamin b12	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylmethionine	chemical	vitamin d	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	s-adenosylmethionine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	s-adenosylmethionine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	s-adenosylmethionine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylmethionine	chemical	vitamin e	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylmethionine	chemical	vitamin b9	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	s-adenosylmethionine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical	vitamin d	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	vitamin b12	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	vitamin b12	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	vitamin b12	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical	vitamin e	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical	vitamin b9	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	vitamin b12	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	vitamin d	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	vitamin d	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	vitamin d	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	chemical	vitamin e	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b9	chemical	vitamin d	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	vitamin d	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	cysteine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	methionine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	vitamin e	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	vitamin b9	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical	s-adenosylhomocysteine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	methionine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	vitamin e	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	vitamin b9	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical	s-adenosylhomocysteine	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	vitamin e	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	vitamin b9	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical	s-adenosylhomocysteine	2	6.28	33414386|24676906	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
vitamin b9	chemical	vitamin e	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	vitamin e	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical	vitamin b9	1	5.28	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
iloperidone	chemical	paliperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	iloperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	iloperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	iloperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical	quetiapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical	quetiapine xr	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical	olanzapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	iloperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical	risperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	paliperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	paliperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	paliperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical	quetiapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical	quetiapine xr	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical	paliperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	paliperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical	risperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	asenapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	asenapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	quetiapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	quetiapine xr	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	olanzapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	fluoxetine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical	risperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	aripiprazole	3	5.473	22784311|22784311|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
aripiprazole	chemical	quetiapine	2	2.0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
aripiprazole	chemical	quetiapine xr	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	olanzapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	fluoxetine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical	risperidone	5	12.419	22784311|22784311|31063671|31063671|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:31063671; Original text:Improvement was greatest in the risperidone group at every assessment period and was statistically significantly better than that in the aripiprazole group at weeks 3 and 6 (p<0.05).|PMID:31063671; Original text:Mean weight gain in the aripiprazole group was significantly less than that in the risperidone group at week 4 (0.62 vs 1.38 kg, p=0.033) and week 10 (1.61 vs 3.31 kg, p<0.001), but the difference became nonsignificant for the 31 patients completing the 3-month extension phase (4.36 vs 5.55 kg, p=0.26).|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
a	chemical	quetiapine	2	2.0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
a	chemical	quetiapine xr	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	olanzapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	fluoxetine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
a	chemical	risperidone	3	5.473	22784311|22784311|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
quetiapine	chemical	quetiapine xr	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical	quetiapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	quetiapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine	chemical	risperidone	2	2.0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
olanzapine	chemical	quetiapine xr	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	quetiapine xr	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine xr	chemical	risperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	olanzapine	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical	risperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical	risperidone	1	1.0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
methionine	chemical	sah	1	5.362	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sah	chemical	sam	1	5.362	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
methionine	chemical	sam	1	5.362	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
serotonin	chemical	serotoninp	2	7.294	15733932|15733932	PMID:15733932; Original text:serotoninP administration significantly increased the levels of serotonin in autistic youngsters but not in normal controls.|PMID:15733932; Original text:Following serotoninP challenge the serotonin levels were significantly higher in autistic patients than in healthy volunteers.
amino acid	chemical	tryptophan	1	1.0	8911222	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).
dha	chemical	epa	3	11.832	28379964|28218722|29562612	PMID:28379964; Original text:In the ω-3 supplementation group, higher baseline body weight predicted less plasma accumulation of both EPA [B = -0.047, (95% CI = -0.077; -0.017), β = -0.54, p = 0.003] and DHA [B = -0.02, (95% CI = -0.034; -0.007), β = -0.52, p = 0.004].|PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
arsenic	chemical	cadmium	1	4.361	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
cadmium	chemical	mercury	1	4.361	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
arsenic	chemical	mercury	1	4.361	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
clomipramine	chemical	haloperidol	1	2.7	11476129	PMID:11476129; Original text:However, significantly fewer individuals receiving clomipramine versus haloperidol were able to complete the trial (37.5% vs. 69.7%, respectively) for reasons related to both side effects and efficacy or behavior problems.
catechol-	chemical	serotonin	1	1.0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
catechol-	chemical	o-methyl	1	1.0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
o-methyl	chemical	serotonin	1	1.0	28656683	PMID:28656683; Original text:The above findings indicated that neither catechol-O-methyl transferase rs4680 nor serotonin transporter serotonin transporterLPR polymorphism significantly affects ASD risk.
naltrexone	chemical	tianeptine	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical	tianeptine	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
methylphenidate	chemical	tianeptine	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
risperidone	chemical	tianeptine	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical	naltrexone	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
methylphenidate	chemical	naltrexone	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
naltrexone	chemical	risperidone	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical	methylphenidate	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical	risperidone	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
methylphenidate	chemical	risperidone	1	2.195	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
oxidized glutathione	chemical	reduced glutathione	2	2.909	32745763|22151477	PMID:32745763; Original text:Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma reduced glutathione and oxidized glutathione levels as well as reduced glutathione:oxidized glutathione ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively).|PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
glutathione	chemical	homocysteine	1	1.0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	chemical	methionine	1	1.0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
homocysteine	chemical	s-adenosylhomocysteine	1	1.0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
folate	chemical	mercury	1	1.0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
mercury	chemical	vitamin b₁₂.	1	1.0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
folate	chemical	vitamin b₁₂.	1	1.0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
glutathione	chemical	gssg	1	1.0	20804367	PMID:20804367; Original text:More notably, these responders exhibited significantly increased plasma concentrations of glutathione and glutathione/GSSG.
glutamine	chemical	p<0.05	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	p<0.05	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	p<0.05	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical	p<0.05	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical	p<0.05	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.05	chemical	phosphocreatine	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	glutamine	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	glutamine	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical	p<0.001	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical	glutamine	2	15.124	22848344|30262887	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).|PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamine	chemical	phosphocreatine	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	creatine	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	p<0.001	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	glutamate	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical	phosphocreatine	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	p<0.001	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	glutamate	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical	phosphocreatine	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical	p<0.001	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical	phosphocreatine	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical	phosphocreatine	1	2.74	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
n-acetyl-aspartate	chemical	n-acetyl-aspartyl-glutamate	1	2.74	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
[123i]-nor-β-cit	chemical	dopamine	1	1.549	22015434	PMID:22015434; Original text:Good clinical responders (n=6) had a decrease (p=0.031) in striatal dopamine transporter binding as assessed using single-photon emission computed tomography with [123I]-nor-β-CIT, whereas poor responders had a trend to an increase.
amino acids	chemical	homocysteine	1	2.738	24167375	PMID:24167375; Original text:The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls.
pcbs	chemical	polychlorinated biphenyls	1	14.251	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
benzene	chemical	pcb 28	1	2.833	25887094	PMID:25887094; Original text:Changes in serum benzene and PCB 28 concentrations showed significant negative correlations with age.
edc	chemical	estrogen	1	5.715	34358505	PMID:34358505; Original text:This is a significant area of study as early brain development is heavily mediated by estrogen and could be particularly sensitive to EDC exposure.
galantamine	chemical	risperidone	1	1.0	24132248	PMID:24132248; Original text:Irritability subscale were equally randomized to receive either galantamine (up to 24 mg/day) or placebo, in addition to risperidone (up to 2 mg/day), for 10 weeks.
glutathione	chemical	sulforaphane	1	5.869	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
comb	chemical	med	1	6.936	22265360	PMID:22265360; Original text:Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02).
b6	chemical	vitamin	1	1.0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b(6	chemical	vitamin	1	1.0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b(6	chemical	b6	1	1.0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
pyruvate	chemical	ubiquinone	1	12.384	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
lactate	chemical	pyruvate	2	24.768	21263444|21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
carnitine	chemical	pyruvate	1	12.384	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
lactate	chemical	ubiquinone	1	12.384	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
carnitine	chemical	ubiquinone	1	12.384	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
carnitine	chemical	lactate	1	12.384	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
fenfluramine	chemical	serotonin	2	2.0	3623815|2936877	PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.|PMID:2936877; Original text:A double-blind cross-over study on the effect of fenfluramine versus placebo in seven autistic boys over a period of 8 months demonstrated a significant decrease in blood serotonin levels during the fenfluramine phase in all subjects.
metformin	chemical	riomet	1	2.195	29620914	PMID:29620914; Original text:We studied the effects of metformin (Riomet®) concentrate on spatial and verbal memory in 51 youth with disorder, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management.
biotin	chemical	vitamin k	1	1.909	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
atp	chemical	nadph	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	nitrotyrosine	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	sam	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	reduced glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	s	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	oxidized glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	nadh	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	gssg	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
atp	chemical	gsh	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	nitrotyrosine	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	sam	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	reduced glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	s	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	oxidized glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	nadph	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	nadph	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	nadph	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	sam	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	reduced glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	s	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	oxidized glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	nitrotyrosine	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	nitrotyrosine	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	nitrotyrosine	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
reduced glutathione	chemical	sam	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
s	chemical	sam	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
oxidized glutathione	chemical	sam	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	sam	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	sam	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
sam	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	sam	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
reduced glutathione	chemical	s	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	reduced glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	reduced glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
reduced glutathione	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	reduced glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
oxidized glutathione	chemical	s	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	s	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	s	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
s	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	s	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	oxidized glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	oxidized glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
oxidized glutathione	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	oxidized glutathione	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	nadh	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	nadh	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	gssg	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gsh	chemical	sulfate	1	1.909	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
epa	chemical	lcpufa	1	4.546	28218722	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).
dha	chemical	lcpufa	1	4.546	28218722	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).
serotonin	chemical	tryptophan	3	3.0	22638012|26746121|26746121	PMID:22638012; Original text:While some individuals with ASD have significant differences in the serotonin system, to our knowledge, no one has investigated its role during facial emotion processing in adults with ASD and control subjects using acute tryptophan depletion (acute tryptophan depletion) and functional magnetic resonance imaging.|PMID:26746121; Original text:Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations were assessed as predictors of buspirone efficacy.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
d	chemical	folate	1	1.281	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
polyunsaturated fatty acids	chemical	vitamin d	1	1.883	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
docosahexaenoic acid	chemical	vitamin d	1	1.883	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
lcpufas	chemical	vitamin d	1	1.883	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
docosahexaenoic acid	chemical	polyunsaturated fatty acids	1	1.883	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
lcpufas	chemical	polyunsaturated fatty acids	1	1.883	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
docosahexaenoic acid	chemical	lcpufas	1	1.883	27334138	PMID:27334138; Original text:There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (specifically docosahexaenoic acid), have the potential to significantly improve the symptoms of autism spectrum disorder (disorder).
cobalt	chemical	magnesium	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
cobalt	chemical	iron	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical	cobalt	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
cobalt	chemical	iodine	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	chemical	magnesium	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical	magnesium	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iodine	chemical	magnesium	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical	iron	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iodine	chemical	iron	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical	iodine	1	3.358	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
copper	chemical	zinc	1	3.358	28665792	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).
dehydroepiandrosterone-sulphate	chemical	serotoninp-	1	0.75	18580847	PMID:18580847; Original text:The serotoninP-induced plasma dehydroepiandrosterone-sulphate responses were significantly higher in autistic patients than in controls.
cortisol	chemical	dehydroepiandrosterone-sulphate	1	0.75	18580847	PMID:18580847; Original text:In baseline conditions, the cortisol/plasma dehydroepiandrosterone-sulphate ratio was significantly higher in autistic patients than in controls.
serotonin	chemical	sertraline	1	1.0	8778118	PMID:8778118; Original text:Although the treatment prescribed for these problems has traditionally been neuroleptic medication, serotonin reuptake inhibitors such as sertraline may result in significant clinical improvement as well as fewer side effects.
cholesterol	chemical	synthesize	1	1.0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
steroid	chemical	synthesize	1	1.0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
cholesterol	chemical	steroid	1	1.0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
dopamine	chemical	homovanillic acid	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical	serotonin	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical	propionic acid	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical	dopamine	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	dopamine	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical	serotonin	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical	propionic acid	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical	homovanillic acid	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	homovanillic acid	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical	serotonin	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical	serotonin	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	serotonin	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical	propionic acid	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	propionic acid	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical	butyric acid	1	5.893	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
5-ht	chemical	carbohydrate-	1	1.0	12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.
serotonin	chemical	serotonin(2ar	1	1.0	18405062	PMID:18405062; Original text:Our study shows that serotonint-LPR and -1438AG serotonin(2Ar) genotypes did not significantly affect serotonin level.
serotonin(2ar	chemical	serotonint	1	1.0	18405062	PMID:18405062; Original text:Our study shows that serotonint-LPR and -1438AG serotonin(2Ar) genotypes did not significantly affect serotonin level.
serotonin	chemical	serotonint	1	1.0	18405062	PMID:18405062; Original text:Our study shows that serotonint-LPR and -1438AG serotonin(2Ar) genotypes did not significantly affect serotonin level.
haloperidol	chemical	risperidone	1	3.941	18080171	PMID:18080171; Original text:Compared to haloperidol, risperidone led to a significantly greater reduction in the Aberrant Behavior Checklist (the Aberrant Behavior Checklist) and Turgay DSM-IV Pervasive Developmental Disorder (Turgay DSM-IV Pervasive Developmental Disorder) scale scores (P < 0.05 and P < 0.01).
homovanillic acid	chemical	magnesium	1	12.095	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
magnesium	chemical	vitamin b6	1	12.095	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
homovanillic acid	chemical	vitamin b6	1	12.095	3886023	PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
risperidone	chemical	rs6280	1	1.0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
25(oh)d	chemical	vitamin d3	1	3.041	28626020	PMID:28626020; Original text:Following vitamin D3 supplementation, there was a significant increase in 25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the primary endpoint.
glutathione	chemical	n-acetylcysteine	1	5.869	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
buspirone	chemical	tryptophan	2	2.0	26746121|26746121	PMID:26746121; Original text:Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations were assessed as predictors of buspirone efficacy.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
buspirone	chemical	serotonin	2	2.0	26746121|26746121	PMID:26746121; Original text:Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations were assessed as predictors of buspirone efficacy.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
n-acetylaspartate	chemical	naa	1	1.0	25817280	PMID:25817280; Original text:The concentrations of N-acetylaspartate (NAA) in these regions of autism spectrum disorders were significantly decreased compared to those in the control group.
and	chemical	androgens	1	1.541	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
cholesterol	chemical	glucose	1	1.0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
glucose	chemical	triglycerides	1	1.0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
cholesterol	chemical	triglycerides	1	1.0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
arbaclofen	chemical	mavoglurant	1	3.13	24173622	PMID:24173622; Original text:Post hoc analyses of studies involving the selective mGluR5 antagonist mavoglurant and the GABAB agonist arbaclofen have uncovered significant therapeutic responses following patient stratification according to FMR1 promoter methylation patterns or baseline severity of social withdrawal, respectively.
coenzyme q10	chemical	epa	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
epa	chemical	vitamins a	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
epa	chemical	folic acid	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	epa	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical	vitamins a	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical	folic acid	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical	dha	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	coenzyme q10	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	chemical	vitamins a	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical	vitamins a	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	vitamins a	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical	folic acid	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	folic acid	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical	dha	1	4.546	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
gaba	chemical	gaba+	1	1.0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
cannabidiol	chemical	gaba+	1	1.0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
cannabidiol	chemical	gaba	1	1.0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba	chemical	simvastatin	1	5.869	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
cysteine	chemical	sulfate	1	1.0	22129897	PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
sulfate	chemical	taurine	1	1.0	22129897	PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
cysteine	chemical	taurine	1	1.0	22129897	PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
heptanoate	chemical	leucylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
leucylglycine	chemical	methylsuccinate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
leucylglycine	chemical	valylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	leucylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	leucylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	leucylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
leucylglycine	chemical	nicotinamide riboside	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	leucylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
leucylglycine	chemical	sarcosine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	methylsuccinate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	valylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	imp	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	heptanoate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	heptanoate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	nicotinamide riboside	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	iminodiacetate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical	sarcosine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
methylsuccinate	chemical	valylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	methylsuccinate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	methylsuccinate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	methylsuccinate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
methylsuccinate	chemical	nicotinamide riboside	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	methylsuccinate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
methylsuccinate	chemical	sarcosine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	valylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	valylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	valylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
nicotinamide riboside	chemical	valylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	valylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
sarcosine	chemical	valylglycine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	imp	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	imp	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	nicotinamide riboside	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	imp	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical	sarcosine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	galactonate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	nicotinamide riboside	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	iminodiacetate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical	sarcosine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	nicotinamide riboside	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	iminodiacetate	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical	sarcosine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	nicotinamide riboside	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
nicotinamide riboside	chemical	sarcosine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical	sarcosine	1	4.282	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
dmsa	chemical	glutathione	1	1.0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
alanine	chemical	glucose	1	6.936	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
ammonia	chemical	clonazepam	1	4.361	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical	zuclopenthixol	1	4.361	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical	zuclopenthixol	2	8.722	26361994|26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.|PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
clonazepam	chemical	venlafaxine	1	4.361	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
venlafaxine	chemical	zuclopenthixol	1	4.361	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
glutamine	chemical	n	1	12.384	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamate	chemical	n	1	12.384	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
n	chemical	oxytocin	1	12.384	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
n	chemical	naa	1	12.384	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamine	chemical	oxytocin	1	12.384	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamine	chemical	naa	1	12.384	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamate	chemical	oxytocin	1	12.384	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamate	chemical	naa	1	12.384	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
naa	chemical	oxytocin	1	12.384	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
